DE60009883D1 - Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonisten - Google Patents
Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonistenInfo
- Publication number
- DE60009883D1 DE60009883D1 DE60009883T DE60009883T DE60009883D1 DE 60009883 D1 DE60009883 D1 DE 60009883D1 DE 60009883 T DE60009883 T DE 60009883T DE 60009883 T DE60009883 T DE 60009883T DE 60009883 D1 DE60009883 D1 DE 60009883D1
- Authority
- DE
- Germany
- Prior art keywords
- alpha
- compounds
- beta
- acetic acid
- acid derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12207199P | 1999-03-01 | 1999-03-01 | |
US122071P | 1999-03-01 | ||
PCT/US2000/004960 WO2000051974A1 (en) | 1999-03-01 | 2000-02-28 | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 - receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60009883D1 true DE60009883D1 (de) | 2004-05-19 |
DE60009883T2 DE60009883T2 (de) | 2005-04-07 |
Family
ID=22400426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60009883T Expired - Fee Related DE60009883T2 (de) | 1999-03-01 | 2000-02-28 | Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonisten |
Country Status (8)
Country | Link |
---|---|
US (2) | US6410781B1 (de) |
EP (1) | EP1161416B1 (de) |
JP (1) | JP2002538135A (de) |
AT (1) | ATE264298T1 (de) |
AU (1) | AU3246600A (de) |
CA (1) | CA2361162A1 (de) |
DE (1) | DE60009883T2 (de) |
WO (1) | WO2000051974A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1161416B1 (de) * | 1999-03-01 | 2004-04-14 | Elan Pharmaceuticals, Inc. | Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonisten |
US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
CA2525934A1 (en) * | 2003-05-20 | 2004-12-02 | Genentech, Inc. | Thiocarbamate inhibitors of alpha-4 integrins |
US20050176755A1 (en) * | 2003-10-31 | 2005-08-11 | Dyatkin Alexey B. | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
WO2005077915A1 (en) * | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Pyridazinones as antagonists of a4 integrins |
BRPI0506676A (pt) * | 2004-02-10 | 2007-05-15 | Janssen Phamaceutica N V | piridazinona uréias como antagonistas de integrinas alfa4 |
WO2006052962A2 (en) | 2004-11-10 | 2006-05-18 | Janssen Pharmaceutica, N.V. | Bicyclic triazole a4 integrin inhibitors |
EP3152188B1 (de) | 2014-06-06 | 2019-02-13 | Allergan, Inc. | Neuartige ep4-agonisten als therapeutische verbindungen |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
KR102641718B1 (ko) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체 |
WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
KR20240035513A (ko) | 2021-07-09 | 2024-03-15 | 알리고스 테라퓨틱스 인코포레이티드 | 항바이러스 화합물 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1593858A1 (de) * | 1967-03-02 | 1970-10-29 | Hoechst Ag | Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten |
JPS5727454B2 (de) | 1975-02-21 | 1982-06-10 | ||
DE2742173A1 (de) | 1977-09-20 | 1979-03-29 | Bayer Ag | Phenoxy-pyridinyl(pyrimidinyl)-alkanole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide |
US4350045A (en) | 1980-06-25 | 1982-09-21 | International Business Machines Corporation | Apparatus and method for characterizing an acoustic field |
IT1211096B (it) | 1981-08-20 | 1989-09-29 | Lpb Ist Farm | Pirimidine e s.triazinici adattivita' ipolipidemizzante. |
US4672065A (en) | 1982-11-19 | 1987-06-09 | Chevron Research Company | N-substituted phenoxyacetamide fungicides |
DE3322720A1 (de) | 1983-06-24 | 1985-01-03 | Chemische Werke Hüls AG, 4370 Marl | Verwendung von in 2-stellung mit (substituierten) aminogruppen substituierten 4-dl-alkylester-(alpha)-alaninyl-6-chlor-s-triazinen als herbizide, insbesondere gegen flughafer |
US4505910A (en) | 1983-06-30 | 1985-03-19 | American Home Products Corporation | Amino-pyrimidine derivatives, compositions and use |
PH22520A (en) | 1984-11-12 | 1988-10-17 | Yamanouchi Pharma Co Ltd | Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them |
US4959364A (en) | 1985-02-04 | 1990-09-25 | G. D. Searle & Co. | Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides |
JPH0784424B2 (ja) | 1987-04-15 | 1995-09-13 | 味の素株式会社 | チロシン誘導体及びその用途 |
EP0330506A3 (de) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | VLA-Proteine |
DE3904931A1 (de) | 1989-02-17 | 1990-08-23 | Bayer Ag | Pyridyl-substituierte acrylsaeureester |
US5030644A (en) | 1989-07-31 | 1991-07-09 | Merck & Co., Inc. | Imidazole compounds and their use as transglutaminase inhibitors |
US4992439A (en) | 1990-02-13 | 1991-02-12 | Bristol-Myers Squibb Company | Pyridazine carboxylic acids and esters |
NZ239846A (en) | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
FR2669339B1 (fr) | 1990-11-21 | 1995-03-03 | Roussel Uclaf | Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives. |
DE4108029A1 (de) | 1991-03-13 | 1992-09-17 | Bayer Ag | Triazinyl-substituierte acrylsaeureester |
IT1247509B (it) | 1991-04-19 | 1994-12-17 | Univ Cagliari | Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus |
EP0633881B1 (de) | 1992-03-11 | 2003-10-29 | Narhex Limited | Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen |
DE4227748A1 (de) | 1992-08-21 | 1994-02-24 | Bayer Ag | Pyridyloxy-acrylsäureester |
JP2848232B2 (ja) | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
US5770573A (en) | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
WO1996001644A1 (en) | 1994-07-11 | 1996-01-25 | Athena Neurosciences, Inc. | Inhibitors of leukocyte adhesion |
IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
CZ288178B6 (en) | 1995-09-29 | 2001-05-16 | Sankyo Co | Milbemycin-5-oxime derivatives substituted in position 13-, and their use |
DE19540798A1 (de) * | 1995-11-02 | 1997-05-07 | Hoechst Ag | Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel |
DE19548709A1 (de) | 1995-12-23 | 1997-07-03 | Merck Patent Gmbh | Tyrosinderivate |
SK176898A3 (en) | 1996-06-28 | 1999-05-07 | Merck Patent Gmbh | Phenylalamine derivatives as integrin inhibitors |
DE19629817A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
DE19647317A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Schering Agrevo Gmbh | Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
DE19647381A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
DE19713000A1 (de) | 1997-03-27 | 1998-10-01 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
PT1005446E (pt) | 1997-08-22 | 2004-06-30 | Hoffmann La Roche | Derivados de n-aroilfenilalanina |
DK1005445T3 (da) | 1997-08-22 | 2004-10-04 | Hoffmann La Roche | N-alkanoylphenylaninderivater |
EE200000428A (et) | 1998-01-23 | 2001-12-17 | Novartis Ag | VLA-4 antagonistid |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
WO1999052493A2 (en) | 1998-04-16 | 1999-10-21 | Texas Biotechnology Corporation | Compounds that inhibit the binding of integrins to their receptors |
EP1161416B1 (de) * | 1999-03-01 | 2004-04-14 | Elan Pharmaceuticals, Inc. | Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonisten |
-
2000
- 2000-02-28 EP EP00910364A patent/EP1161416B1/de not_active Expired - Lifetime
- 2000-02-28 DE DE60009883T patent/DE60009883T2/de not_active Expired - Fee Related
- 2000-02-28 WO PCT/US2000/004960 patent/WO2000051974A1/en active IP Right Grant
- 2000-02-28 AT AT00910364T patent/ATE264298T1/de not_active IP Right Cessation
- 2000-02-28 US US09/514,773 patent/US6410781B1/en not_active Expired - Fee Related
- 2000-02-28 JP JP2000602202A patent/JP2002538135A/ja active Pending
- 2000-02-28 CA CA002361162A patent/CA2361162A1/en not_active Abandoned
- 2000-02-28 AU AU32466/00A patent/AU3246600A/en not_active Abandoned
-
2002
- 2002-05-20 US US10/147,884 patent/US6545160B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE264298T1 (de) | 2004-04-15 |
WO2000051974A1 (en) | 2000-09-08 |
DE60009883T2 (de) | 2005-04-07 |
CA2361162A1 (en) | 2000-09-08 |
AU3246600A (en) | 2000-09-21 |
EP1161416A1 (de) | 2001-12-12 |
EP1161416B1 (de) | 2004-04-14 |
US6545160B2 (en) | 2003-04-08 |
JP2002538135A (ja) | 2002-11-12 |
US20030018195A1 (en) | 2003-01-23 |
US6410781B1 (en) | 2002-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1072608A1 (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | |
MXPA01007335A (es) | Derivados de acilo los cuales tratan trastornos relacionados con alfa4 beta1 integrina y cd49d/cd29 (vla-4). | |
TW200603788A (en) | Multivalent vla-4 antagonists comprising polymer moieties | |
NO20000451L (no) | Forbindelser som inhiberer leukocyttadhesjon mediert av VLA-4 | |
EA200401561A1 (ru) | Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов | |
NO20000414L (no) | Benzylforbindelser som inhiberer leukocytt adhesjon mediert av VLA-4 | |
NO20000412L (no) | Dipeptidforbindelser som inhiberer leukocytt-adhesjon mediert av VLA-4 | |
NO20000452L (no) | Sulfonylerte dipeptidforbindelser som inhiberer leukocyttadhesjon mediert av VLA-4 | |
CA2290745A1 (en) | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 | |
DK1940826T3 (da) | Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4 | |
DE60009883D1 (de) | Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonisten | |
WO2000043354A3 (en) | Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 | |
WO2002008203A3 (en) | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 | |
ZA200803016B (en) | Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 | |
WO2000043371A3 (en) | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 | |
WO2002008201A3 (en) | Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4 | |
WO2000043413A3 (en) | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de | ||
8370 | Indication related to discontinuation of the patent is to be deleted | ||
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |